<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Skin and Venereal Diseases</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Skin and Venereal Diseases</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский журнал кожных и венерических болезней</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9588</issn><issn publication-format="electronic">2412-9097</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">699955</article-id><article-id pub-id-type="doi">10.17816/dv699955</article-id><article-id pub-id-type="edn">GXFZLY</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DERMATOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДЕРМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Mental disorders in patients with severe forms of chronic dermatoses: an observational cross-sectional study in a hospital-based consecutive population</article-title><trans-title-group xml:lang="ru"><trans-title>Психические расстройства у пациентов с тяжёлыми формами хронических дерматозов: наблюдательное поперечное исследование на госпитальной последовательной выборке</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1613-2510</contrib-id><contrib-id contrib-id-type="spin">8701-7958</contrib-id><name-alternatives><name xml:lang="en"><surname>Dorozhenok</surname><given-names>Igor Yu.</given-names></name><name xml:lang="ru"><surname>Дороженок</surname><given-names>Игорь Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент</p></bio><email>dorozhenok_i_yu@staff.sechenov.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2482-1754</contrib-id><contrib-id contrib-id-type="spin">2500-7989</contrib-id><name-alternatives><name xml:lang="en"><surname>Olisova</surname><given-names>Olga Yu.</given-names></name><name xml:lang="ru"><surname>Олисова</surname><given-names>Ольга Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, чл.-корр. РАН</p></bio><email>olisovaolga@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3619-206X</contrib-id><contrib-id contrib-id-type="spin">8253-7096</contrib-id><name-alternatives><name xml:lang="en"><surname>Koriakin</surname><given-names>Danila A.</given-names></name><name xml:lang="ru"><surname>Корякин</surname><given-names>Данила Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>danila110920021@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The First Sechenov Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-04-28" publication-format="electronic"><day>28</day><month>04</month><year>2026</year></pub-date><pub-date date-type="pub" iso-8601-date="2026-05-17" publication-format="electronic"><day>17</day><month>05</month><year>2026</year></pub-date><volume>29</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>147</fpage><lpage>158</lpage><history><date date-type="received" iso-8601-date="2025-12-29"><day>29</day><month>12</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-03-14"><day>14</day><month>03</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Эко-Вектор</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-05-17"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://eco-vector.com/for_authors.php#07</ali:license_ref></license></permissions><self-uri xlink:href="https://rjsvd.com/1560-9588/article/view/699955">https://rjsvd.com/1560-9588/article/view/699955</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> The skin is involved not only in barrier and immune defense but also in the formation of bodily self-awareness and the integration of somatic information into the structure of the self. In severe forms of chronic dermatoses, this function is impaired by persistent sensory stress (itching, pain), health threats, and the need for long-term systemic therapy, which contributes to increased mental comorbidity.</p> <p><bold>AIM:</bold> This study aimed to develop a structure of comorbid mental disorders with a comprehensive assessment of psychosomatic relationships in patients with severe forms of chronic dermatoses.</p> <p><bold>METHODS:</bold> A single-center, observational, cross-sectional study was conducted on a consecutive sample of patients who consecutively visited the clinic between 2017 and 2025. A total of 445 patients (158 men, 287 women; mean age 42.3 ± 13.7 years) were included. Inclusion criteria were a severe form of chronic dermatosis (psoriasis, atopic dermatitis, lichen planus, true acantholytic pemphigus, true eczema, acne vulgaris, vitiligo, rosacea, and seborrheic dermatitis) and the presence of a comorbid mental disorder according to the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10).</p> <p><bold>RESULTS:</bold> Comorbid mental pathology manifested mainly as adjustment disorder (F43.2) in 103 patients (23.1%), depressive episode (F32.0) in 66 (14.8%), and hypochondriacal disorder (F45.2) in 63 (14.2%). A transnosological hypochondriacal nosogenic complex was identified in 400 patients (89.9%). Three clinical types were identified: (1) depressive-hypochondriacal (<italic>n</italic> = 250, 62.5%) — hypothymia with hypochondriacal phobias, with a significant correlation between the Clinical Symptom Index and anxiety levels (<italic>r</italic> = 0.49, <italic>p</italic> &lt; 0.001), depression (<italic>r</italic> = 0.52, <italic>p</italic> &lt; 0.001), and DLQI (ρ = 0.46, <italic>p</italic> &lt; 0.001); (2) masked hypochondria (<italic>n</italic> = 123, 30.8% ) — a rational-overcoming response style with no correlation between the Clinical Symptom Index and psychometric indicators; (3) aberrant hypochondria (<italic>n</italic> = 27, 6.7%) — paradoxical denial of illness despite objectively severe somatic status.</p> <p><bold>CONCLUSION:</bold> The proposed typology facilitates diagnosis and creates the basis for a differentiated psychotherapeutic and psychopharmacological approach in psychodermatology.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Кожа участвует не только в барьерной и иммунной защите, но и в формировании телесного самоощущения и интеграции соматической информации в структуре «Я». При тяжёлых формах хронических дерматозов эта функция нарушается под влиянием персистирующего сенсорного стресса (зуд, боль), угрозы здоровью и необходимости длительной системной терапии, что способствует росту психической коморбидности.</p> <p><bold>Цель исследования</bold> ― разработка структуры коморбидных психических расстройств с комплексной оценкой психосоматических взаимосвязей у пациентов с тяжёлыми формами хронических дерматозов.</p> <p><bold>Методы.</bold> В одноцентровое наблюдательное поперечное (cross-sectional) исследование, выполненное на выборке пациентов, последовательно обратившихся в клинику в период с 2017 по 2025 год, включены 445 пациентов (158 мужчин, 287 женщин, средний возраст 42,3 ± 13,7 года). Критериями включения в исследование были тяжёлая форма хронического дерматоза (псориаз, атопический дерматит, красный плоский лишай, истинная акантолитическая пузырчатка, исинная экзема, вульгарные угри, витилиго, розацеа, себорейный дерматит), наличие коморбидного психического расстройства по Международной статистической классификации болезней и проблем, связанных со здоровьем, Десятого пересмотра (МКБ-10).</p> <p><bold>Результаты.</bold> Коморбидная психическая патология проявлялась преимущественно расстройством адаптации (F43.2; <italic>n</italic> = 103, 23,1%), депрессивным эпизодом (F32.0; <italic>n</italic> = 66, 14,8%), ипохондрическим расстройством (F45.2; <italic>n</italic> = 63, 14,2%). У 400 (89,9%) пациентов выявлен транснозологический ипохондрический нозогенный комплекс. Выделены три клинических типа: депрессивно-ипохондрический (<italic>n</italic> = 250, 62,5%) ― гипотимия с ипохондрическими фобиями со значимой корреляцией между индексом клинических симптомов и уровнями тревоги (r = 0,49, <italic>p</italic> &lt; 0,001), депрессии (r = 0,52, <italic>p</italic> &lt; 0,001) и DLQI (ρ = 0,46, <italic>p</italic> &lt; 0,001); маскированная ипохондрия (<italic>n</italic> = 123, 30,8%) ― рационально-преодолевающий стиль реагирования без корреляции индекса клинических симптомов с психометрическими показателями; аберрантная ипохондрия (<italic>n</italic> = 27; 6,7%) ― парадоксальное отрицание болезни при объективно тяжёлом соматическом статусе.</p> <p><bold>Заключение.</bold> Предложенная типология облегчает диагностику и создаёт основу для дифференцированного психотерапевтического и психофармакологического подхода в психодерматологии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>dermatoses</kwd><kwd>psychosomatics</kwd><kwd>comorbidity</kwd><kwd>psychodermatology</kwd><kwd>adjustment disorders</kwd><kwd>anxiety</kwd><kwd>depression</kwd><kwd>obsessive-compulsive disorder</kwd><kwd>OCD</kwd><kwd>hypochondria</kwd><kwd>quality of life</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дерматозы</kwd><kwd>психосоматика</kwd><kwd>коморбидность</kwd><kwd>психодерматология</kwd><kwd>расстройства адаптации</kwd><kwd>тревога</kwd><kwd>депрессия</kwd><kwd>обсессивно-компульсивное расстройство</kwd><kwd>ОКР</kwd><kwd>ипохондрия</kwd><kwd>качество жизни</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Balieva F, Abebe DS, Dalgard FJ, Lien L. Risk of developing psychiatric disease among adult patients with skin disease: a 9-year national register follow-up study in Norway. Skin Health Dis. 2023;3(6):e294. doi: 10.1002/ski2.294 EDN: EMWNPS</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Henderson AD, Adesanya E, Mulick A, et al. Common mental health disorders in adults with inflammatory skin conditions: nationwide population-based matched cohort studies in the UK. BMC Med. 2023;21(1):285. doi: 10.1186/s12916-023-02948-x EDN: JQAPNF</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Seth D, Cheldize K, Brown D, Freeman EF. Global burden of skin disease: inequities and innovations. Curr Dermatol Rep. 2017;6(3):204–210. doi: 10.1007/s13671-017-0192-7 EDN: ZWGRFR</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970. doi: 10.1056/NEJMra1505557</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Branisteanu DE, Pirvulescu RA, Spinu AE, et al. Metabolic comorbidities of psoriasis (review). Exp Ther Med. 2022;23(2):179. doi: 10.3892/etm.2021.11102 EDN: HXEZNK</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017–2033. doi: 10.1007/s12325-020-01346-6 EDN: RCSYAA</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Pompili M, Innamorati M, Trovarelli S, et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(1 Suppl):61–66. doi: 10.1177/0300060515593253</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Petrova NN, Smirnova IO, Likhonos LM. Comparative evaluation of various approaches to therapy of patients with psoriasis. V.M. Bekhterev review of psychiatry and medical psychology. 2013;(1):63–70. (In Russ.) EDN: PZGGPH</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kern C, Wan J, LeWinn KZ, et al. Association of atopic dermatitis and mental health outcomes across childhood: a longitudinal cohort study. JAMA Dermatol. 2021;157(10):1200–1208. doi: 10.1001/jamadermatol.2021.2657 EDN: PPUIVE</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Glavina A, Zanze L, Barac E, et al. Oral lichen planus: key features of etiopathogenesis, diagnosis, and management. Acta Dermatovenerol Alp Pannonica Adriat. 2025;34(3):109–115. doi: 10.15570/actaapa.2025.21 EDN: TKTIOF</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Warnakulasuriya S, Ramos-García P, González-Moles MÁ. Oral lichen planus and systemic diseases. J Dent Res. 2026;105(1):31–41. doi: 10.1177/00220345251385966 EDN: YWRICF</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Koning AC, van der Meulen M, Schaap D, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(6):e1442–e1451. doi: 10.1210/clinem/dgad701 EDN: DHPDHK</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289. doi: 10.1016/j.det.2017.02.002 EDN: YFMGET</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16. doi: 10.1159/000370220 EDN: SRSGUL</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020 EDN: LEPJCT</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Yoon S, Kim K, Shin K, et al. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2024;38(1):52–61. doi: 10.1111/jdv.19426 EDN: ZBXFTD</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zaenglein AL. Acne vulgaris. N Engl J Med. 2018;379(14):1343–1352. doi: 10.1056/NEJMcp1702493</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Trave I, Donadoni R, Cozzani E, et al. Acne fulminans and its multiple associated factors: a systematic review. Eur J Dermatol. 2023;33(6):624–634. doi: 10.1684/ejd.2023.4629 EDN: JWWUWM</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Magin P, Prentice S. Isotretinoin and adverse psychiatric effects. JAMA Dermatol. 2024;160(1):19–20. doi: 10.1001/jamadermatol.2023.4577 EDN: NQKAVS</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne―update 2016―short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–1268. doi: 10.1111/jdv.13776</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749–758; quiz 759–760. doi: 10.1016/j.jaad.2014.08.028</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Chernyshov PV, Finlay AY, Tomas-Aragones L, et al. Quality of life measurement in rosacea. Position statement of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2023;37(5):954–964. doi: 10.1111/jdv.18918 EDN: QQRDDQ</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Del Rosso JQ, Tanghetti E, Webster G, et al. Update on the management of rosacea from the American Acne &amp; Rosacea Society (AARS). J Clin Aesthet Dermatol. 2019;12(6):17–24.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–349. doi: 10.1016/j.jaci.2016.06.010 EDN: XTYENB</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583–596. doi: 10.1016/S0140-6736(24)02519-4</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Gabes M, Donhauser T, Piontek K, et al. Measurement properties of quality-of-life outcome measures for children and adults with eczema: a systematic review update 2.0. Pediatr Allergy Immunol. 2023;34(3):e13934. doi: 10.1111/pai.13934 EDN: DUAWUD</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Borda LJ, Wikramanayake TC. Seborrheic dermatitis and dandruff: a comprehensive review. J Clin Investig Dermatol. 2015;3(2):10.13188/2373-1044.1000019. doi: 10.13188/2373-1044.1000019</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Cortés-Correa C, Piquero-Casals J, Chaparro-Reyes D, et al. Facial seborrheic dermatitis in hiv-seropositive patients: evaluation of the efficacy and safety of a non-steroidal cream containing piroctone olamine, biosaccharide gum-2 and stearyl glycyrrhetinate: a case series. Clin Cosmet Investig Dermatol. 2022;15:483–488. doi: 10.2147/CCID.S344807 EDN: FAWKZQ</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2024;90(3):597–604. doi: 10.1016/j.jaad.2022.12.017 EDN: WRYPQG</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Cömert A, Akbaş B, Kılıç EZ, et al. Psychiatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey. Am J Clin Dermatol. 2013;14(4):335–342. doi: 10.1007/s40257-013-0019-7 EDN: UJTIDI</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi: 10.1016/S0140-6736(14)60763-7</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Subtil J, Carvalho R, Rebelo AF, Subtil P. Autoimmune polyglandular syndrome type 3: a case report. Cureus. 2024;16(12):e76152. doi: 10.7759/cureus.76152 EDN: AWRDNC</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Kapur S, Goyal E, Kumar A, et al. Psychiatric morbidity among patients suffering from Vitiligo. Ind Psychiatry J. 2023;32(Suppl 1):S131–S135. doi: 10.4103/ipj.ipj_220_23</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978. doi: 10.3389/fimmu.2019.00978 EDN: IJEEON</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Malik AM, Tupchong S, Huang S, et al. An updated review of pemphigus diseases. Medicina (Kaunas). 2021;57(10):1080. doi: 10.3390/medicina57101080 EDN: EUOLBO</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Hébert V, Hamwi S, Tancrède-Bohin E, et al. Optimizing pemphigus management with rituximab and short-term relapse predictors. JAMA Dermatol. 2025;161(4):399–405. doi: 10.1001/jamadermatol.2024.6130 EDN: CKXKOO</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126. doi: 10.1186/1741-7015-11-126 EDN: QRHFUI</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Volel BA, Ragimova AA, Kuznetsova IV, Burchakov DI. Current concepts of stress-dependent disorders of the menstrual cycle. Obstetrics and gynecology. 2016;(12):34–40. doi: 10.18565/aig.2016.12.34-40 EDN: XGVCRP</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Ritvo P, Knyahnytska Y, Pirbaglou M, et al. Online mindfulness-based cognitive behavioral therapy intervention for youth with major depressive disorders: randomized controlled trial. J Med Internet Res. 2021;23(3):e24380. doi: 10.2196/24380 EDN: CTINTK</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Smulevich AB, Volel BA, Ternovaya ES, Nikitina YM. Pantogam activ (D-, L-hopantenic acid) in the treatment of cognitive and anxiety disorders in patients with arterial hypertension. S.S. Korsakov journal of neurology and psychiatry. 2015;115(12):40–49. doi: 10.17116/jnevro201511511240-49 EDN: VLMQTZ</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kern S, Jerg-Bretzke L, Beschoner P. Psychotherapeutic burnout interventions: an umbrella review. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024;67(11):1279–1287. (In German) doi: 10.1007/s00103-024-03961-y EDN: PYABQS</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Miller WR. The evolution of motivational interviewing. Behav Cogn Psychother. 2023;51(6):616–632. doi: 10.1017/S1352465822000431 EDN: QDITDV</mixed-citation></ref></ref-list></back></article>
